Signifor Approval Highlights Success Of Novartis’ Parallel Development Strategy
Executive Summary
Following its approval in Europe earlier in 2012, the FDA approval of Signifor for Cushing’s disease is just the latest piece of a strategy to bring the injectable to market in multiple indications, including acromegaly.